# Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Source: https://onco.cc/trials/nct03379428/  
OnCo record `nct03379428` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab and Ibrutinib in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.

## Summary

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT03379428 by US Oncology Research, with 34 participants enrolled, started 2017-11-29 and due to reach its primary completion in 2025-01. Interventions recorded: Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg and Ibrutinib 420 mg.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03379428
- Phase: 1/2
- Setting: Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
- Sponsor: US Oncology Research
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT03379428: https://clinicaltrials.gov/study/NCT03379428

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [McKesson / The US Oncology Network](https://onco.cc/companies/mckesson-us-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct03379428.json